Full Press Release Details
Immuron Announces Resignation of Board Member
Melbourne, Australia, October
17, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing
oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, announced today
that Mr. Richard Jay Berman has resigned as director of the Company, effective immediately.
"The Board thanks Richard for his varied contributions
to Immuron during his time as a director of the company," said Dr. Gary S. Jacob, CEO of Immuron. "Richard's
broad experience as a board member provided us with a unique and fresh perspective regarding our activities during our many meetings
together. I also valued his input during the many conversations he and I had on a variety of topics covering Immuron's activities.
Speaking for all of my colleagues, we wish Richard well in his future endeavors."
Immuron Limited (ASX: IMC, NASDAQ: IMRN),
is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies
for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one
commercial asset Travelan generating revenue. Immuron's lead clinical candidate, IMM-124E, is presently
being developed as a drug to prevent Travelers' Diarrhea. Immuron's second clinical-stage asset, IMM-529, targets
Clostridium difficile Infections (CDI), and is presently in a clinical trial in CDI patients. These products together with
the Company's other preclinical immunotherapy pipeline products currently under development targeting immune-related and
infectious diseases are anticipated to meet pressing needs in the global immunotherapy market.
For more information
visit: http://www.immuron.com